CRISPR Therapeutics
CRSP
CRSP
275 hedge funds and large institutions have $2.91B invested in CRISPR Therapeutics in 2020 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 93 increasing their positions, 62 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
275
Holders Change
+19
Holders Change %
+7.42%
% of All Funds
5.65%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.12%
New
64
Increased
93
Reduced
62
Closed
45
Calls
$76.8M
Puts
$88.7M
Net Calls
-$11.9M
Net Calls Change
-$21.6M
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$162M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$42.4M |
| 3 |
BlackRock
New York
|
+$29.3M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$26.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.8M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$21.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$16.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.7M |
| 4 |
GTP
Global Thematic Partners
New York
|
-$14.1M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$11.1M |
